Stock.io

Open

High

Low

Volume

Average Volume

P/E

Forward P/E

Market cap

52W H

52W L

Beta

Dividend yield

Website

Sector

Industry

Number of employees

Short term outlook

Long term outlook

News:

Loading details...

Open58.35

High58.63

Low49.96

Volume69.27M

Average Volume20.55M

P/E13.82

Forward P/E12.85

Market cap223.51B

52W H93.80

52W L43.08

Beta0.40

Dividend yield0.03

Open

High

Low

Volume

Average Volume

P/E

Forward P/E

Market cap

52W H

52W L

Beta

Dividend yield

Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Websitehttps://www.novonordisk.com

SectorHealthcare

IndustryDrug Manufacturers - General

Number of employees

78,554

Short term outlookBearish

Long term outlookBullish

Website

Sector

Industry

Number of employees

Short term outlook

Long term outlook

News:

As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?
Barchart
•
6 hours ago
Novo Nordisk shares plunge amid lower 2026 sales outlook
Investing.com
•
11 hours ago
Novo Nordisk Forecasts 2026 Sales Decline; Shares Fall
MT Newswires
•
11 hours ago
Novo Nordisk data shows CagriSema ‘superior’ in Phase 3 trial, says UBS
TipRanks
•
11 hours ago
NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study
Zacks
•
13 hours ago